Latest Articles

Publication Date
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - Clinical Oncology News

Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer Clinical Oncology News

Published: Aug. 3, 2026, 3:32 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - clinicaloncology.com

Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer clinicaloncology.com

Published: Aug. 3, 2026, 3:31 p.m.
Women, health practitioners commemorate Endometriosis month - NewVision.co.ug

Women, health practitioners commemorate Endometriosis month NewVision.co.ug

Published: Aug. 3, 2026, 2 p.m.
Health: Endometriosis linked to slightly higher risk of earl - NewVision.co.ug

Health: Endometriosis linked to slightly higher risk of earl NewVision.co.ug

Published: Aug. 3, 2026, 2 p.m.
Endometriosis Treatment Market Size to Exceed $6.53 Billion By 2035 - SNS Insider

Endometriosis Treatment Market Size to Exceed $6.53 Billion By 2035 SNS Insider

Published: Aug. 3, 2026, 12:43 p.m.
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openPR.com

Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openPR.com

Published: Aug. 3, 2026, 10:50 a.m.
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openpr.com

Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openpr.com

Published: Aug. 3, 2026, 10:50 a.m.
Lotus Endometriosis Institute Expands Advanced Evaluations As Demand Grows - markets.businessinsider.com

Lotus Endometriosis Institute Expands Advanced Evaluations As Demand Grows markets.businessinsider.com

Published: Aug. 3, 2026, 7:47 a.m.
Whole-body thermal therapies for symptom management and well-being in people assigned female at birth with chronic pelvic pain, dysmenorrhoea, endometriosis or adenomyosis: a scoping review protocol.

Dysmenorrhoea is one of the most frequent manifestations of chronic pelvic pain. Endometriosis and adenomyosis are among the most common pathological causes of secondary dysmenorrhoea. Symptoms often persist despite treatment, …

Published: Aug. 3, 2026, midnight
Low-energy extracorporeal shock wave therapy is associated with reduced inflammation and fibrosis in an E2-induced rat model of endometriosis and remains effective under menopause-mimicking conditions.

Endometriosis is an estrogen-dependent inflammatory disorder marked by ectopic lesions, chronic pelvic inflammation, and frequent recurrence. Extracorporeal shock wave therapy (ESWT) is a non-invasive modality with anti-inflammatory and regenerative potential, …

Published: Aug. 3, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!